Research Headlines – Collecting the world’s viruses, empowering urgent research

  • by

Ebola, Zika, MERS, COVID-19? An EU-funded collection of mammalian viruses is supporting researchers around the globe in their efforts to shed new light on old and emerging illnesses and advance their treatment and control. This Research Infrastructure is the world’s largest archive of such pathogens… Read More »

Research Headlines – Collecting the world’s viruses, empowering urgent research

Research Headlines – Collecting the world’s viruses, empowering urgent research

  • by

Ebola, Zika, MERS, COVID-19? An EU-funded collection of mammalian viruses is supporting researchers around the globe in their efforts to shed new light on old and emerging illnesses and advance their treatment and control. This Research Infrastructure is the world’s largest archive of such pathogens… Read More »

Research Headlines – Collecting the world’s viruses, empowering urgent research

Research Headlines – Collecting the world’s viruses, empowering urgent research

  • by

Ebola, Zika, MERS, COVID-19? An EU-funded collection of mammalian viruses is supporting researchers around the globe in their efforts to shed new light on old and emerging illnesses and advance their treatment and control. This Research Infrastructure is the world’s largest archive of such pathogens… Read More »Research Headlines – Collecting the world’s viruses, empowering urgent research

Drug repurposing patent documents vs peer review: patent information comes more than 600 days earlier on average

  • by

This article was originally published by Hermann Mucke & Peter Mucke in Future Drug Discovery under a Attribution-NonCommercial-NoDerivatives 4.0 Unported License. https://doi.org/10.4155/fdd-2020-0001. Drug developers require access to scientific information in… The post Drug repurposing patent documents vs peer review: patent information comes more than 600… Read More »Drug repurposing patent documents vs peer review: patent information comes more than 600 days earlier on average

Dr.Reddy’s – Openings for Freshers and Experienced Any Graduates || Any Graduates

  • by

Dr.Reddy’s – Openings for Freshers and Experienced Any Graduates || Any Graduates Dear All, If your profile is suitable for Pharma sales job, please share atrupaattal@drreddys.com Also share with your friends and network. Hiring PSR (Professional Service Representative): Education: Any graduate or post graduate. Should have provisional… Read More »Dr.Reddy’s – Openings for Freshers and Experienced Any Graduates || Any Graduates

Syngene International Looking For Bbrc-analytical Research and Development Department

  • by

Syngene International Looking For Bbrc-analytical Research and Development Department Syngene International Hiring Any Graduate . Syngene International Limited Incorporated in the year 1994, Syngene International is one of India¢¢s premier contract research and manufacturing organizations in providing customized service. Our services encompasses all across discovery… Read More »Syngene International Looking For Bbrc-analytical Research and Development Department

Alembic Pharmaceuticals Looking For Executive / Senior Executive API – QC Reviewer

  • by

Alembic Pharmaceuticals Looking For Executive / Senior Executive API-QcRm Reviewer Alembic Pharmaceuticals Hiring B.Pharm,M.Pharm.M.sc. Alembic Pharmaceuticals Limited, with an established presence in the Indian pharma industry has a proud, historical track record going back one hundred years. With a turnover in excess of Rs. 3000… Read More »Alembic Pharmaceuticals Looking For Executive / Senior Executive API – QC Reviewer

Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy

  • by

Annals of Pharmacotherapy, Volume 54, Issue 10, Page 1001-1009, October 2020. Objective:To review the efficacy and safety of onasemnogene abeparvovec-xioi (Zolgensma) in the treatment of spinal muscular atrophy (SMA).Data Sources:An English-language literature search of PubMed, MEDLINE, and Ovid (1946 to December 2019) was completed using… Read More »Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy

Urgent vacancy at Mankind

  • by

Urgent vacancy at Mankind *Vacancy*of Medical Representative in *Mankind Pharma Ltd*Div-Future (cardiometabolic ) At *HQ- BHOPAL* Qualification-Graduate/D.PharmaExperienced person will be preferred (6month to 1year Experienced & Age limit -27Years)Contact-Durgesh JaiswalMob.No – *9993498485* Visit above links for more information

Coronavirus: 5 Ways You Can Use Social Media and Digital Marketing to Help the Public During the COVID-19 Pandemic

  • by

Today I am going to share some important ways that doctors, hospitals and healthcare marketers can use social media to inform the public during the COVID-19 crisis. Priority One: Use social media to convince people to comply with social distancing, and consequently help us all,… Read More »Coronavirus: 5 Ways You Can Use Social Media and Digital Marketing to Help the Public During the COVID-19 Pandemic

Macleods Pharmaceuticals Hiring For Clinical Trial – Medical Doctor

  • by

Macleods Pharmaceuticals Hiring For Clinical Trial – Medical Doctor Macleods Pharmaceuticals Hiring MBBS .Macleods, India¢¢s Fastest growing pharmaceutical company, with a strong R&D and own Bio-equivalence centre, manufacturing sites approved by USFDA & WHO Geneva, ranked among the top pharmaceutical companies with a strength of… Read More »Macleods Pharmaceuticals Hiring For Clinical Trial – Medical Doctor

Harman Finochem Recruiting For Technician in Production Department For OSD

  • by

Harman Finochem Recruiting For Technician in Production Department For OSD Harman Finochem Hiring B.Sc .Harman Finochem Limited is a leading India-based Pharmaceutical Company which specializes in the manufacture and export of more than 45 Active Pharmaceutical Ingredients (APls) of which 10 are Essential Drugs as… Read More »Harman Finochem Recruiting For Technician in Production Department For OSD

Lupin Recruiting For Operator/officer For Mdi/dpi Production/packing

  • by

Lupin Recruiting For Operator/officer For Mdi/dpi Production/packing Lupin Hiring B.Pharma. Lupin Limited is one of India’s largest manufacturers of bulk actives and formulations. The principal bulk actives manufactured by it include Rifampicin, Pyrazinamide, Ethambutol (anti-TB), Cephalosporins (anti-infectives) and cardiovasculars. The company also possesses competencies in… Read More »Lupin Recruiting For Operator/officer For Mdi/dpi Production/packing

Sourcing investigational COVID-19 drugs

  • by

Are you trying to source investigational COVID-19 drugs? We’ve pulled out all the relevant supply-chain resources at https://www.drugpatentwatch.com/covid-19/ . Let me know what more we can do.. edit: updated url submitted by /u/drugpatentwatch [link] [comments]

Association Between Antipsychotics and Osteoporosis Based on Real-World Data

  • by

Annals of Pharmacotherapy, Volume 54, Issue 10, Page 988-995, October 2020. Background:Osteoporosis, which is a major public health concern, has been known to reduce health-related quality of life. Some studies have suggested that antipsychotics could perhaps cause osteoporosis by increasing serum prolactin levels. However, the… Read More »Association Between Antipsychotics and Osteoporosis Based on Real-World Data

Association Between Antipsychotics and Osteoporosis Based on Real-World Data

  • by

Annals of Pharmacotherapy, Ahead of Print. Background: Osteoporosis, which is a major public health concern, has been known to reduce health-related quality of life. Some studies have suggested that antipsychotics could perhaps cause osteoporosis by increasing serum prolactin levels. However, the association between antipsychotics and… Read More »Association Between Antipsychotics and Osteoporosis Based on Real-World Data

Association Between Antipsychotics and Osteoporosis Based on Real-World Data

  • by

Annals of Pharmacotherapy, Ahead of Print. Background: Osteoporosis, which is a major public health concern, has been known to reduce health-related quality of life. Some studies have suggested that antipsychotics could perhaps cause osteoporosis by increasing serum prolactin levels. However, the association between antipsychotics and… Read More »Association Between Antipsychotics and Osteoporosis Based on Real-World Data

Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  • by

Annals of Pharmacotherapy, Volume 54, Issue 10, Page 1010-1015, October 2020. Objective:To review the efficacy and safety of niraparib for the treatment of recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer (OC, FTC, and PPC).Data Sources:A literature search via MEDLINE through PubMed from August… Read More »Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  • by

Annals of Pharmacotherapy, Ahead of Print. Objective: To review the efficacy and safety of niraparib for the treatment of recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer (OC, FTC, and PPC). Data Sources: A literature search via MEDLINE through PubMed from August 2013 to… Read More »Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  • by

Annals of Pharmacotherapy, Ahead of Print. Objective: To review the efficacy and safety of niraparib for the treatment of recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer (OC, FTC, and PPC). Data Sources: A literature search via MEDLINE through PubMed from August 2013 to… Read More »Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Advancing through partnerships

  • by

  If any reminder were needed of the power of collaboration in healthcare, it is the global efforts underway to stem the current coronavirus outbreak and to develop treatments for it.   Chris Round, Merck’s Head of International Operations & Global Core Franchises, speaking to… Read More »Advancing through partnerships

Research Headlines – COVID-19: the EU is ready to respond

  • by

Across the EU, many people are worried about the novel coronavirus and its rapid spread. The EU project PREPARE, which began in 2014, is responding to COVID-19 by rapidly assessing Europe’s preparedness and deploying vital clinical research.

Research Headlines – COVID-19: the EU is ready to respond

  • by

Across the EU, many people are worried about the novel coronavirus and its rapid spread. The EU project PREPARE, which began in 2014, is responding to COVID-19 by rapidly assessing Europe’s preparedness and deploying vital clinical research.

Research Headlines – COVID-19: the EU is ready to respond

  • by

Across the EU, many people are worried about the novel coronavirus and its rapid spread. The EU project PREPARE, which began in 2014, is responding to COVID-19 by rapidly assessing Europe’s preparedness and deploying vital clinical research.

Research Headlines – COVID-19: the EU is ready to respond

  • by

Across the EU, many people are worried about the novel coronavirus and its rapid spread. The EU project PREPARE, which began in 2014, is responding to COVID-19 by rapidly assessing Europe’s preparedness and deploying vital clinical research.

Research Headlines – COVID-19: the EU is ready to respond

  • by

Across the EU, many people are worried about the novel coronavirus and its rapid spread. The EU project PREPARE, which began in 2014, is responding to COVID-19 by rapidly assessing Europe’s preparedness and deploying vital clinical research.

Research Headlines – COVID-19: the EU is ready to respond

  • by

Across the EU, many people are worried about the novel coronavirus and its rapid spread. The EU project PREPARE, which began in 2014, is responding to COVID-19 by rapidly assessing Europe’s preparedness and deploying vital clinical research.

Outcomes Associated With Resuming Direct Oral Anticoagulant Therapy Following Admission for a Gastrointestinal Bleed

  • by

Annals of Pharmacotherapy, Volume 54, Issue 10, Page 975-980, October 2020. Background:Although direct oral anticoagulants (DOACs) carry a lower bleeding risk compared with warfarin, gastrointestinal bleeds (GIB) are a known complication. There are limited data observing outcomes associated with resuming DOACs following a GIB.Objective:The purpose… Read More »Outcomes Associated With Resuming Direct Oral Anticoagulant Therapy Following Admission for a Gastrointestinal Bleed

Outcomes Associated With Resuming Direct Oral Anticoagulant Therapy Following Admission for a Gastrointestinal Bleed

  • by

Annals of Pharmacotherapy, Ahead of Print. Background: Although direct oral anticoagulants (DOACs) carry a lower bleeding risk compared with warfarin, gastrointestinal bleeds (GIB) are a known complication. There are limited data observing outcomes associated with resuming DOACs following a GIB. Objective: The purpose of this… Read More »Outcomes Associated With Resuming Direct Oral Anticoagulant Therapy Following Admission for a Gastrointestinal Bleed

Outcomes Associated With Resuming Direct Oral Anticoagulant Therapy Following Admission for a Gastrointestinal Bleed

  • by

Annals of Pharmacotherapy, Ahead of Print. Background: Although direct oral anticoagulants (DOACs) carry a lower bleeding risk compared with warfarin, gastrointestinal bleeds (GIB) are a known complication. There are limited data observing outcomes associated with resuming DOACs following a GIB. Objective: The purpose of this… Read More »Outcomes Associated With Resuming Direct Oral Anticoagulant Therapy Following Admission for a Gastrointestinal Bleed

3 things to know about coronavirus disease and your Marketplace coverage

  • by

{% box %}
Coronavirus.gov is the source for the latest information about COVID-19 prevention, symptoms, and answers to common questions.

USA.gov has the latest information about what the U.S. Government is doing in response to COVID-19.
{% endbox %}

You may be hearing about the coronavirus (officially called 2019-novel coronavirus or COVID-19) in the news. Currently, the rules in your Marketplace health plan for treatment for COVID-19, remain the same as for the treatment of any other viral infection. Check with your health insurance company for their specific benefits and coverage policy. Here are some other things to know about how your Marketplace health plan works when it comes to coronavirus:

Read More »3 things to know about coronavirus disease and your Marketplace coverage

Advancing Laboratory Diagnostic Stewardship for Healthcare-Associated Infections (HAIs), Antibiotic Resistance, and Sepsis

  • by

Emily Curren DVM, MPH On December 9, 2019, CDC’s Division of Healthcare Quality Promotion (DHQP) hosted a meeting at CDC headquarters in Atlanta, Georgia, on improving patient safety through diagnostic stewardship. Meeting attendees represented academia; federal partners; and professional, industry, and patient representative organizations. The… Read More »Advancing Laboratory Diagnostic Stewardship for Healthcare-Associated Infections (HAIs), Antibiotic Resistance, and Sepsis

Effectiveness of Steroid Treatment for Sudden Sensorineural Hearing Loss: A Meta-analysis of Randomized Controlled Trials

  • by

Annals of Pharmacotherapy, Volume 54, Issue 10, Page 949-957, October 2020. Background:The best way to administer steroids for sudden sensorineural hearing loss (SSHL) is still unclear. The present study was aimed at estimating the efficacy of steroids by intratympanic, systemic, and combined therapy (CT) routes.Methods:A… Read More »Effectiveness of Steroid Treatment for Sudden Sensorineural Hearing Loss: A Meta-analysis of Randomized Controlled Trials

Effectiveness of Steroid Treatment for Sudden Sensorineural Hearing Loss: A Meta-analysis of Randomized Controlled Trials

  • by

Annals of Pharmacotherapy, Ahead of Print. Background: The best way to administer steroids for sudden sensorineural hearing loss (SSHL) is still unclear. The present study was aimed at estimating the efficacy of steroids by intratympanic, systemic, and combined therapy (CT) routes. Methods: A systematic literature… Read More »Effectiveness of Steroid Treatment for Sudden Sensorineural Hearing Loss: A Meta-analysis of Randomized Controlled Trials

Effectiveness of Steroid Treatment for Sudden Sensorineural Hearing Loss: A Meta-analysis of Randomized Controlled Trials

  • by

Annals of Pharmacotherapy, Ahead of Print. Background: The best way to administer steroids for sudden sensorineural hearing loss (SSHL) is still unclear. The present study was aimed at estimating the efficacy of steroids by intratympanic, systemic, and combined therapy (CT) routes. Methods: A systematic literature… Read More »Effectiveness of Steroid Treatment for Sudden Sensorineural Hearing Loss: A Meta-analysis of Randomized Controlled Trials

Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials

  • by

Annals of Pharmacotherapy, Volume 54, Issue 9, Page 872-878, September 2020. Objective: To review phase II and III clinical trial data to evaluate the efficacy and safety of the halobetasol propionate/tazarotene (HP/TAZ) combination lotion (Duobrii), a medication approved by the Food and Drug Administration in… Read More »Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials

Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials

  • by

Annals of Pharmacotherapy, Ahead of Print. Objective: To review phase II and III clinical trial data to evaluate the efficacy and safety of the halobetasol propionate/tazarotene (HP/TAZ) combination lotion (Duobrii), a medication approved by the Food and Drug Administration in April 2019 for adults with… Read More »Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials

To Block or Not: Updates in Neuromuscular Blockade in Acute Respiratory Distress Syndrome

  • by

Annals of Pharmacotherapy, Volume 54, Issue 9, Page 899-906, September 2020. Objective: To review and evaluate neuromuscular blocking agents (NMBAs) in critically ill patients with acute respiratory distress syndrome (ARDS). Data Sources: A literature search utilizing PubMed was performed (January 1991 to January 2020) using… Read More »To Block or Not: Updates in Neuromuscular Blockade in Acute Respiratory Distress Syndrome

To Block or Not: Updates in Neuromuscular Blockade in Acute Respiratory Distress Syndrome

  • by

Annals of Pharmacotherapy, Ahead of Print. Objective: To review and evaluate neuromuscular blocking agents (NMBAs) in critically ill patients with acute respiratory distress syndrome (ARDS). Data Sources: A literature search utilizing PubMed was performed (January 1991 to January 2020) using the following search terms: (neuromuscular… Read More »To Block or Not: Updates in Neuromuscular Blockade in Acute Respiratory Distress Syndrome

Dose-Dependent Hyperkalemia Among Hospitalized, HIV-Infected Patients Receiving Sulfamethoxazole/Trimethoprim

  • by

Annals of Pharmacotherapy, Volume 54, Issue 9, Page 852-857, September 2020. Background: Sulfamethoxazole-trimethoprim (SXT) therapy is commonly used in HIV-infected patients and is associated with hyperkalemia and elevated serum creatinine (SCr). Objective: The purpose of this study was to examine the frequency of hyperkalemia and… Read More »Dose-Dependent Hyperkalemia Among Hospitalized, HIV-Infected Patients Receiving Sulfamethoxazole/Trimethoprim

Dose-Dependent Hyperkalemia Among Hospitalized, HIV-Infected Patients Receiving Sulfamethoxazole/Trimethoprim

  • by

Annals of Pharmacotherapy, Ahead of Print. Background: Sulfamethoxazole-trimethoprim (SXT) therapy is commonly used in HIV-infected patients and is associated with hyperkalemia and elevated serum creatinine (SCr). Objective: The purpose of this study was to examine the frequency of hyperkalemia and elevated SCr in hospitalized, HIV-infected… Read More »Dose-Dependent Hyperkalemia Among Hospitalized, HIV-Infected Patients Receiving Sulfamethoxazole/Trimethoprim

Improved Glycemic Control Outcomes Regardless of Mental Health Disorders in a Pharmacist-Endocrinologist Diabetes Intense Medical Management (DIMM) “Tune Up” Clinic

  • by

Annals of Pharmacotherapy, Volume 54, Issue 9, Page 858-865, September 2020. Background: Previous studies show patients with type 2 diabetes (T2D) and a mental health (MH) disorder exhibit poorer glycemic control compared with those without. Objective: Compare mean change in glycosylated hemoglobin (A1C) after 6… Read More »Improved Glycemic Control Outcomes Regardless of Mental Health Disorders in a Pharmacist-Endocrinologist Diabetes Intense Medical Management (DIMM) “Tune Up” Clinic

Improved Glycemic Control Outcomes Regardless of Mental Health Disorders in a Pharmacist-Endocrinologist Diabetes Intense Medical Management (DIMM) “Tune Up” Clinic

  • by

Annals of Pharmacotherapy, Ahead of Print. Background: Previous studies show patients with type 2 diabetes (T2D) and a mental health (MH) disorder exhibit poorer glycemic control compared with those without. Objective: Compare mean change in glycosylated hemoglobin (A1C) after 6 months in the Diabetes Intense… Read More »Improved Glycemic Control Outcomes Regardless of Mental Health Disorders in a Pharmacist-Endocrinologist Diabetes Intense Medical Management (DIMM) “Tune Up” Clinic

The Best discount online pharmacy

  • by

The first online pharmacy (http://rxlegal-online.com) which offers the easiest way of placing order, the fastest shipping to any place on the globe and the cheapest prices on the web. Great deals and free shipping for orders over $200! submitted by /u/Trevor-Mc [link] [comments]

244 Drug Patents With Claims Containing “consisting essentially of” may be Unenforceable

  • by

In a recent court ruling, the U.S. Court of Appeals for the Federal Circuit (CAFC) denied a petition to rehear arguments regarding the invalidity of patent claims containing the phrase… The post 244 Drug Patents With Claims Containing “consisting essentially of” may be Unenforceable appeared… Read More »244 Drug Patents With Claims Containing “consisting essentially of” may be Unenforceable

IMPROOF Workshop – 16th Global Congress on Process Safety – 16 August 2020, Houston, TX, USA

  • by

IMPROOF is a European Union Horizon 2020 project, which aims to improve the energy efficiency of steam cracking furnaces while reducing emissions of greenhouse gases and NOx. This workshop is organized by the IMPROOF consortium, registration is open for all stakeholders from both industry and… Read More »IMPROOF Workshop – 16th Global Congress on Process Safety – 16 August 2020, Houston, TX, USA

Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents

  • by

Annals of Pharmacotherapy, Volume 54, Issue 9, Page 879-898, September 2020. Objectives: To discuss (1) recent and emerging data for pharmacological management of untreated and relapsed/refractory (R/R) mantle cell lymphoma (MCL) with agents approved in the United States, (2) important considerations for toxicity monitoring and… Read More »Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents

Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents

  • by

Annals of Pharmacotherapy, Ahead of Print. Objectives: To discuss (1) recent and emerging data for pharmacological management of untreated and relapsed/refractory (R/R) mantle cell lymphoma (MCL) with agents approved in the United States, (2) important considerations for toxicity monitoring and management, and (3) preliminary data… Read More »Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents

TEDMED 2020 Meetups

  • by

TEDMED Meetups, uniquely designed conversations, engage the entire TEDMED community to share their individual perspectives and voices to help improve humanity’s health. Read on to view some of the details of these captivating conversations taking place at TEDMED 2020. Meetup 1 Tuesday, March 3rd, 8:00… Read More »TEDMED 2020 Meetups

Standardized Volume Dosing Protocol of 23.4% Hypertonic Saline for Pediatric Critical Care: Initial Experience

  • by

Annals of Pharmacotherapy, Volume 54, Issue 9, Page 866-871, September 2020. Background: Standardized volume dosing of 23.4% hypertonic saline (HTS) exists for adults, but the concentration, dosing and administration of HTS in pediatrics is variable. With emerging pediatric experience of 23.4% HTS, a standard volume… Read More »Standardized Volume Dosing Protocol of 23.4% Hypertonic Saline for Pediatric Critical Care: Initial Experience

Standardized Volume Dosing Protocol of 23.4% Hypertonic Saline for Pediatric Critical Care: Initial Experience

  • by

Annals of Pharmacotherapy, Ahead of Print. Background: Standardized volume dosing of 23.4% hypertonic saline (HTS) exists for adults, but the concentration, dosing and administration of HTS in pediatrics is variable. With emerging pediatric experience of 23.4% HTS, a standard volume dose approach may be helpful.… Read More »Standardized Volume Dosing Protocol of 23.4% Hypertonic Saline for Pediatric Critical Care: Initial Experience

The Revised Starling Equation: The Debate of Albumin Versus Crystalloids Continues

  • by

Annals of Pharmacotherapy, Volume 54, Issue 9, Page 921-927, September 2020. Objectives: The purpose of this critical narrative review is to discuss the revised Starling equation for microvascular fluid exchange and the associated implications for intravenous fluid administration. Data Sources: PubMed (1946 to December 2019)… Read More »The Revised Starling Equation: The Debate of Albumin Versus Crystalloids Continues

The Revised Starling Equation: The Debate of Albumin Versus Crystalloids Continues

  • by

Annals of Pharmacotherapy, Ahead of Print. Objectives: The purpose of this critical narrative review is to discuss the revised Starling equation for microvascular fluid exchange and the associated implications for intravenous fluid administration. Data Sources: PubMed (1946 to December 2019) and EMBASE (1947 to December… Read More »The Revised Starling Equation: The Debate of Albumin Versus Crystalloids Continues

Current System of Overseeing Drug Trials in Developing Countries by the FDA Is Dangerous

  • by

Annals of Pharmacotherapy, Volume 54, Issue 9, Page 928-932, September 2020. Clinical research used to substantiate Food and Drug Administration (FDA) drug approval is increasingly being conducted overseas. One of the enticements to move overseas is unequal oversight by the FDA, and these differences can… Read More »Current System of Overseeing Drug Trials in Developing Countries by the FDA Is Dangerous

Current System of Overseeing Drug Trials in Developing Countries by the FDA Is Dangerous

  • by

Annals of Pharmacotherapy, Ahead of Print. Clinical research used to substantiate Food and Drug Administration (FDA) drug approval is increasingly being conducted overseas. One of the enticements to move overseas is unequal oversight by the FDA, and these differences can result in poor quality research… Read More »Current System of Overseeing Drug Trials in Developing Countries by the FDA Is Dangerous

Real-World Evaluation of Dosing in Patients Converted From Insulin Glargine (Lantus) to Insulin Glargine (Basaglar)

  • by

Annals of Pharmacotherapy, Volume 54, Issue 9, Page 846-851, September 2020. Background: Basaglar, insulin glargine (BGlar; Eli Lilly, Indianapolis, IN), a follow-on biologic, was developed after the patent for Lantus, insulin glargine (LGlar; Sanofi-Aventis, Paris, France) expired. Objective: To compare the dosing and hemoglobin A1C… Read More »Real-World Evaluation of Dosing in Patients Converted From Insulin Glargine (Lantus) to Insulin Glargine (Basaglar)

Real-World Evaluation of Dosing in Patients Converted From Insulin Glargine (Lantus) to Insulin Glargine (Basaglar)

  • by

Annals of Pharmacotherapy, Ahead of Print. Background: Basaglar, insulin glargine (BGlar; Eli Lilly, Indianapolis, IN), a follow-on biologic, was developed after the patent for Lantus, insulin glargine (LGlar; Sanofi-Aventis, Paris, France) expired. Objective: To compare the dosing and hemoglobin A1C (A1C)-lowering effects of BGlar compared… Read More »Real-World Evaluation of Dosing in Patients Converted From Insulin Glargine (Lantus) to Insulin Glargine (Basaglar)

Meet the Session Hosts!

  • by

As TEDMED 2020 nears we are excited to announce our 2020 Session Hosts. Playing an integral role at TEDMED, our Session Hosts guide us through our amazing Stage Program, helping to connect the themes and ideas shared by our Speakers throughout the program. In addition… Read More »Meet the Session Hosts!

Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class

  • by

Annals of Pharmacotherapy, Volume 54, Issue 8, Page 795-803, August 2020. Objective: To review the new drug class of calcitonin gene-related peptide antagonists (monoclonal antibodies) and their clinical relevance in migraine prophylaxis. Data Sources: A literature search was performed in PubMed (January 2009 to November… Read More »Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class

The Tasmanian Atrial Fibrillation Study (TAFS): Differences in Stroke Prevention According to Sex

  • by

Annals of Pharmacotherapy, Volume 54, Issue 9, Page 837-845, September 2020. Background: There are limited Australian data on sex differences in oral anticoagulant (OAC) prescribing in atrial fibrillation (AF) and ongoing debate regarding the optimal approach to stroke risk assessment and OAC prescribing in female… Read More »The Tasmanian Atrial Fibrillation Study (TAFS): Differences in Stroke Prevention According to Sex

The Tasmanian Atrial Fibrillation Study (TAFS): Differences in Stroke Prevention According to Sex

  • by

Annals of Pharmacotherapy, Ahead of Print. Background: There are limited Australian data on sex differences in oral anticoagulant (OAC) prescribing in atrial fibrillation (AF) and ongoing debate regarding the optimal approach to stroke risk assessment and OAC prescribing in female patients with AF. Objective: The… Read More »The Tasmanian Atrial Fibrillation Study (TAFS): Differences in Stroke Prevention According to Sex

Research Headlines – Handy mozzie-checking platform to help keep malaria at bay

  • by

To spray or not to spray – and potentially, what with: EU-funded researchers are developing a sophisticated system to facilitate analyses of mosquitoes and their mechanisms of resistance to insecticides, support data sharing and refine decision-making processes. Scientists in Cameroon are helping to advance this… Read More »Research Headlines – Handy mozzie-checking platform to help keep malaria at bay

Research Headlines – Handy mozzie-checking platform to help keep malaria at bay

  • by

To spray or not to spray – and potentially, what with: EU-funded researchers are developing a sophisticated system to facilitate analyses of mosquitoes and their mechanisms of resistance to insecticides, support data sharing and refine decision-making processes. Scientists in Cameroon are helping to advance this… Read More »Research Headlines – Handy mozzie-checking platform to help keep malaria at bay

Efficacy of Conversion to Aflibercept for Diabetic Macular Edema Previously Refractory to Bevacizumab or Ranibizumab: A Meta-analysis of High-Quality Nonrandomized Studies

  • by

Annals of Pharmacotherapy, Volume 54, Issue 8, Page 750-756, August 2020. Background: Aflibercept has been widely used in treating diabetic macular edema (DME). However, the effect of aflibercept in treating DME refractory to bevacizumab or ranibizumab has not been well established. Objective: To assess the… Read More »Efficacy of Conversion to Aflibercept for Diabetic Macular Edema Previously Refractory to Bevacizumab or Ranibizumab: A Meta-analysis of High-Quality Nonrandomized Studies

TEDMED 2020 Sessions Announced

  • by

Inspiring a healthier humanity requires us to push ourselves forward to drive progress while reflecting on the astonishing accomplishments we have achieved. At TEDMED 2020, we will connect with an invisible force that has been propelling humanity forward for millennia—wonder. To experience wonder is to… Read More »TEDMED 2020 Sessions Announced

GVK Biosciences Walk In for Synthesis R and D /Analytical R and D 1st Feb 2020

  • by

GVK Biosciences Walk In  for Synthesis R and D /Analytical R and D 1st Feb 2020 GVK Biosciences Pvt. LtdRecruitment January 2020 M.Sc. Organic Chemistry for Synthesis R&D /Analytical R&D @ Bengaluru.Please go through following summary of vacancy. GVK Biosciences Pvt. Ltd selection as below Full Details Post… Read More »GVK Biosciences Walk In for Synthesis R and D /Analytical R and D 1st Feb 2020

Urgent vacancy at Usv ltd

  • by

Urgent vacancy at Usv ltd *Vacancy for the Post of MR* *USV* Private Limited *HQ* –  Nagpur Minimum 6 Month Experience. Qualification:- BSc, B Pharm, D Pharm. Interested Candidate Can Call and can Send Resume on following mail id. Vipin RamtekeArea Manager.9673972240.Email id– vipinramteke2007@gmail.com Visit… Read More »Urgent vacancy at Usv ltd

GLAND PHARMA LTD – Walk-In Interviews for Freshers and Experience on 1st Feb’ 2020

  • by

GLAND PHARMA LTD – Walk-In Interviews for Freshers and Experience on 1st Feb’ 2020  Greetings from Gland Pharma Limited!! We have urgent Requirement forMicrobiology Department. If you are interested you can walk-in for an interaction on01st February 2020 Between 09.00 AM to 11.00 AM. Job Specification: Experience:… Read More »GLAND PHARMA LTD – Walk-In Interviews for Freshers and Experience on 1st Feb’ 2020

Urgent Vacancy at IPCA Pharmaceuticals

  • by

Urgent Vacancy at IPCA H.Q.INDORE (MR) IPCA LABORATORIES BIONOVA DIVISION POST :  MR ( Med. Rep.)  *H.Q. :-INDORE*  Any Graduate , Age No Bar Min 1 Years  Experiences in Pharma Contact MADAN MOHAN RATHORE MOB:-8602796453 Visit above links for more information

Impact of an Antimicrobial Stewardship Team on Reducing Antiretroviral Medication Errors

  • by

Annals of Pharmacotherapy, Volume 54, Issue 8, Page 767-774, August 2020. Background: Numerous interventions have been used to reduce medication errors related to antiretroviral (ARV) therapy for hospitalized patients with HIV. Objective: This study assessed the impact of an antimicrobial stewardship (ASP) team intervention on… Read More »Impact of an Antimicrobial Stewardship Team on Reducing Antiretroviral Medication Errors

Pharmacokinetics of Trastuzumab After Subcutaneous and Intravenous Administration in Obese Patients

  • by

Annals of Pharmacotherapy, Volume 54, Issue 8, Page 775-779, August 2020. Background: Subcutaneous trastuzumab (T-SC) administration does not allow the historical target concentration of 20 µg/mL for efficacy to be reached, from the start of treatment in patients with a body mass index (BMI) >30… Read More »Pharmacokinetics of Trastuzumab After Subcutaneous and Intravenous Administration in Obese Patients

Reflections on the Second Report of the WHO’s NCD Commission

  • by

Countries around the world face different and unique public health challenges that sometimes require regional or even international collaboration to solve. One such challenge that has prompted calls for international cooperation are non-communicable diseases, or NCDs for short. Cardiovascular disease, cancer, diabetes, chronic respiratory diseases,… Read More »Reflections on the Second Report of the WHO’s NCD Commission

Association of Antibiotic Treatment Duration With Recurrence of Uncomplicated Urinary Tract Infection in Pediatric Patients

  • by

Annals of Pharmacotherapy, Volume 54, Issue 8, Page 757-766, August 2020. Background: Gaps and inconsistencies in published information about optimal antibiotic treatment duration for uncomplicated urinary tract infection (UTI) in pediatric patients pose a dilemma for antibiotic stewardship. Objective: Evaluate the association of antibiotic treatment… Read More »Association of Antibiotic Treatment Duration With Recurrence of Uncomplicated Urinary Tract Infection in Pediatric Patients

Associations Between Obesity and the Effectiveness of Anti–Tumor Necrosis Factor-α Agents in Inflammatory Bowel Disease Patients: A Literature Review and Meta-analysis

  • by

Annals of Pharmacotherapy, Volume 54, Issue 8, Page 729-741, August 2020. Background: A total of 15% to 40% of adult inflammatory bowel disease (IBD) patients are obese. The influence of obesity on anti-tumor necrosis factor-α (anti-TNF-α) treatment in IBD patients is not consistent. Objective: To… Read More »Associations Between Obesity and the Effectiveness of Anti–Tumor Necrosis Factor-α Agents in Inflammatory Bowel Disease Patients: A Literature Review and Meta-analysis

Introducing The Hive 2020!

  • by

We are happy to announce the TEDMED 2020 Hive Program, which will feature inspiring entrepreneurs and their organizations. As always, this year’s Hive class is made of Innovators representing early- to mid-stage organizations across 6 categories: 1) Life Sciences & Therapeutics 2) Med-Tech & Med-Device… Read More »Introducing The Hive 2020!

Adrenal Insufficiency and Response to Stress Dose Hydrocortisone in Patients With Cirrhosis and Vasopressor Dependency Using Cirrhosis-Specific Cortisol Thresholds

  • by

Annals of Pharmacotherapy, Volume 54, Issue 8, Page 742-749, August 2020. Background: Cortisol thresholds defining adrenal insufficiency (AI) in some cirrhosis-specific studies differ from those recommended by the SCCM/ESICM (Society of Critical Care Medicine/European Society of Intensive Care Medicine) guidelines, which may influence treatment decisions.… Read More »Adrenal Insufficiency and Response to Stress Dose Hydrocortisone in Patients With Cirrhosis and Vasopressor Dependency Using Cirrhosis-Specific Cortisol Thresholds

Evaluating innovative portfolios and preparing for branded, 505(b)(2), and generic competition

  • by

Here’s a copy of the recent talk on Evaluating innovative portfolios and preparing for branded, 505(b)(2), and generic competition. It’s based on the book Make Better Decisions, which distills insights… The post Evaluating innovative portfolios and preparing for branded, 505(b)(2), and generic competition appeared first… Read More »Evaluating innovative portfolios and preparing for branded, 505(b)(2), and generic competition

Five Healthcare Trends in 2020: Your Cheat Sheet

  • by

<div class="right-align"> <a class="btn btn-blue _gt" data-category="Hospital" data-action="Click-Button" data-label="Blog-Five Healthcare Trends in 2020: Your Cheat Sheet" href="https://www.kindredhealthcare.com/docs/default-source/default-document-library/kindred-hospitals-healthcare-trends-in-2020.pdf?sfvrsn=acbf8dea_2" title="Five Healthcare Trends in 2020: Your Cheat Sheet" target="_blank">Download this article as a PDF</a></div> <br /> <p>In 2020, our nation&rsquo;s healthcare delivery and payment environment will continue its… Read More »Five Healthcare Trends in 2020: Your Cheat Sheet

MorphoSys Reports Submission of Tafasitamab’s BLA to the US FDA to Treat Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

  • by

Shots: The BLA submission is based on L-MIND P-II trial data results assessing Tafasitamab + lenalidomide in patients with r/r DLBCL and retrospective observational matched control cohort Re-MIND evaluating efficacy outcomes of r/r DLBCL patients who received Tafasitamab + lenalidomide vs lenalidomide monothx Re-MIND has… Read More »MorphoSys Reports Submission of Tafasitamab’s BLA to the US FDA to Treat Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

Clover Reports First Patient Dosing in P-III Trial with SCB-808 (biosimilar, etanercept) in China

  • by

Shots: The P-III study involves assessing of SCB-808 (SC) vs Enbrel (SC) in patients with ankylosing spondylitis (radiographic axial spondyloarthritis) to evaluate its safety, efficacy and PK The company utilizes its Trimer-Tag technology platform to develop novel therapies targeting trimerization-dependent pathways and is also leveraging… Read More »Clover Reports First Patient Dosing in P-III Trial with SCB-808 (biosimilar, etanercept) in China

GenScript Signs an Agreement with Selecxine to Develop Therapies for Immuno-Oncology

  • by

Shots: GenScript will be responsible for all pre-clinical pharmacy research and IND filling in Selecxine’s project which is based on cytokine-antibody complexes The company provided development solutions in different hosts tailored to customers and provided the preparation and purification solutions for the final complex,; further… Read More »GenScript Signs an Agreement with Selecxine to Develop Therapies for Immuno-Oncology

Acceleron Signs a License Agreement with Fulcrum for the Identification of Therapies to Treat Pulmonary Diseases

  • by

Shots: Fulcrum to receive $10M upfront, reimbursement for R&D costs, research, development and commercial milestone of up to $295M for first product commercialized and additional payments $143.5M for all subsequent products commercialized plus royalties on sales of product Acceleron to get rights to access Fulcrum’s… Read More »Acceleron Signs a License Agreement with Fulcrum for the Identification of Therapies to Treat Pulmonary Diseases

BeiGene’s Tislelizumab Receives NMPA’s Approval for the Treatment of 2L Classical Hodgkin’s Lymphoma (cHL)

  • by

Shots: The approval is based on P-II BGB-A317-203 (NCT03209973) trial which involves assessing of tislelizumab with median follow up of 14 months The study resulted in ORR as 76.9% and CR as 61.5% with no fatal adverse reactions. BieGene’s Tislelizumab is the first drug to… Read More »BeiGene’s Tislelizumab Receives NMPA’s Approval for the Treatment of 2L Classical Hodgkin’s Lymphoma (cHL)

Eli Lilly Opens its P-III LIBRETTO-531 Clinical Trial for LOXO-292 (selpercatinib) to Treat RET-Mutant Medullary Thyroid Cancer (MTC) Patients

  • by

Shots: The second P-III LIBRETTO-531 involves assessing of selpercatinib vs physician’s choice of cabozantinib or vandetanib in 400 patients in ratio (2:1) with advanced or metastatic RET-mutant MTC who have received no prior systemic therapy for metastatic disease The study will have efficacy endpoints as… Read More »Eli Lilly Opens its P-III LIBRETTO-531 Clinical Trial for LOXO-292 (selpercatinib) to Treat RET-Mutant Medullary Thyroid Cancer (MTC) Patients

AstraZeneca and Merck & Co’s Lynparza Receive the US FDA’s Approval as a 1L Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer

  • by

Shots: The approval follows the US FDA Oncologic drugs Advisory Committee (ODAC) on 17 Dec based on P-III POLO trial, which involves assessing of Lynparza tablets (300 mg bid) as maintenance monothx vs. PBO in 154 patients in ratio (3:2) with gBRCAm metastatic pancreatic cancer… Read More »AstraZeneca and Merck & Co’s Lynparza Receive the US FDA’s Approval as a 1L Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer

Zai Lab’s Zejula (niraparib) Receives NMPA’s Approval as Maintenance Therapy for Patients with Recurrent Ovarian Cancer in China

  • by

Shots: Zejula (niraparib) is an oral once-daily poly (ADP-ribose) polymerase (PARP) inhibitor used as a maintenance therapy for adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy The NMPA approval of Zejula… Read More »Zai Lab’s Zejula (niraparib) Receives NMPA’s Approval as Maintenance Therapy for Patients with Recurrent Ovarian Cancer in China

Eisai Reports Results of DAYVIGO (lemborexant) in P-III SUNRISE 1 Study in Patients with Insomnia Disorder

  • by

Shots: The P-III SUNRISE 1 (Study 304) study involves assessing of DAYVIGO (lemborexant, 5 or 10 mg) vs an active comparator or PBO in 1,006 patients with insomnia disorder aged 55 years of age or older Results of P-III study@ 5/10 mg of DAYVIGO: headache… Read More »Eisai Reports Results of DAYVIGO (lemborexant) in P-III SUNRISE 1 Study in Patients with Insomnia Disorder

Clover Reports Dosing of SCB-808 (biosimilar, etanercept) in P-III Trial in China

  • by

Shots: The P-III study involves assessing of SCB-808 vs Enbrel in patients with AS (axSpA) via SC administration SCB-808 is being developed in the prefilled syringe formulation which is ready for injection and can be self-administered by the patients, thus overwhelming the current Enbrel biosimilar… Read More »Clover Reports Dosing of SCB-808 (biosimilar, etanercept) in P-III Trial in China